Office Number: 203-815-5782



CaroGen Corporation is an emerging vaccine immunotherapy company employing a virus-like vesicle (VLV) platform technology developed at Yale University School of Medicine and exclusively licensed for the development and commercialization of vaccine immunotherapies worldwide.


Our vision is to create different, potentially transformative first-in-class nanoparticle therapeutic vaccine immunotherapies designed to engage the body’s immune system to both recognize and fight off infectious diseases and cancer.  The company is leveraging the VLV platform and developing a portfolio of vaccine candidates against the following infections/diseases:


  • Chronic Hepatitis B Viral Infection (CHB) in collaboration with Yale School of Medicine and Albany Medical College
  • Clostridium difficile, a bacterial infection, in collaboration with the University of Connecticut Medical School/Health Center
  • Colon Cancer Immunotherapy in collaboration with researchers at the University of Connecticut


The hepatitis B program is CaroGen's lead program and has completed initial proof-of-concept testing in animals which was published in August 2015 in the Journal of Virology.  Worldwide, approximately 240 million people live with CHB and 600,000 die each year from HBV-associated liver disease and cancer.  The HBV program is undergoing optimization for selection of a clinical candidate capable of stimulating the immune system to multiple HBV target antigens.


Clostridium difficile is a microbial infection that causes severe diarrhea and is a CDC urgent threat due to antimicrobial resistance.  It is currently estimated that there are 500,000 infections per year in the US resulting 29,000 deaths/year.   There are currently no vaccines for either the prevention or treatment of C. difficile and limited antimicrobial drugs available to treat established infections


Colon cancer is the third leading cause of cancer-related deaths in the United States when men and women are considered separately, and the second leading cause when both sexes are combined. Colon cancer was estimated to have caused over 49,000 deaths in 2016.


CaroGen Expands its Board of Directors and Development Leadership Team


Farmington, CT - April 17, 2017:  CaroGen today announced an important addition to its Board of Directors (Dr. Jo Viney) and two key senior executive level scientists (Dr. Steven Mason and Dr. Timur Yarovinsky) to its immunotherapy discovery and development team. Click here to read the full press release


CaroGen and University of Connecticut Colon Cancer Immunotherapy Collaboration Highlighted in Colon Cancer News Today


Farmington, CT - January 26, 2017:  CaroGen and researchers at the University of Connecticut have initiated a collaboration on development of a colon cancer immunotherapy.  This collaboration was highlighted in Colon Cancer News Today.  Click here to read the full article.


UCONN Health Researchers Collaborate with CaroGen Corporation to Develop Vaccine to Treat Colon Cancer


Farmington, CT - November 8, 2016:  The University of Connecticut and CaroGen Corporation, an emerging immunotherapy company, today announced a collaboration aimed at developing a therapeutic vaccine for treatment of patients with colon cancer.  CaroGen’s proprietary technology platform will be applied to a specific target studied by UConn Health’s Dr. Kepeng Wang Ph.D., Assistant Professor of Immunology. Click here to read the full press release


CaroGen Forms Zika Vaccine Consortium


Farmington, CT - November 7, 2016:  CaroGen Corporation, announced today that it has formed a consortium comprising CaroGen, the University of Connecticut and Yale University School of Medicine scientists to accelerate the development of a Zika virus vaccine. Click here to read the full press release.


CaroGen Raiess $1M in Series A Funds


Farmington, CT - October 19, 2016:  CaroGen Corporation announced today that it has raised $1 million dollars through GP Fortune Investment Partners (GPFI), LLC, to advance the company's Heptatis B Virus (HBV) immunotherapy.  Click here to read the full press release.


CaroGen in the News:

August 8, 2016:  CaroGen’s CEO Bijan Almassian was profiled by the Hartford Business Journal where he discusses CaroGen's technology, products to treat or prevent Hepatitis B, Zika and C. difficile infections and financing.  Click here to read the full interview.


July 5, 2016: Connecticut Senators Murphy and Blumenthal pushing for Zika virus response funding.  Click here for the story.


SPARK Commercialization Grant Award for C. difficile Vaccine


Farmington, CT -  April 18, 2016: CaroGen announced today that University of Connecticut collaborator, Dr. Kamal Khanna, was awarded a SPARK Commercialization Fund grant from the University of Connecticut. The grant is to support the research and development of a VLV-based vaccine against C. difficile infection.  The award will support the creation of candidate VLV vaccines and testing their immunogenicity in preclinical models. Click here to read the award notification from SPARK.



CT Backs CaroGen’s Quest to Fight Cancer, Hepatitis B


March 7, 2016:  An interview with CaroGen’s President and CEO was published in the Hartford Business Journal where he provides an update on CaroGen’s product development:  Click here to read the full interview.



CaroGen Announces Publication of HBV Vaccine Preclinical Research


Hamden CT - August 17, 2015 - CaroGen Corporation, an emerging vaccine company, today announced the electronic publication of a research article entitled “Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection,” which appeared in the August online issue of the Journal of Virology.


-Click to Read More-



CaroGen Fostering Vaccine Development  Collaborations with Yale & UConn and Establishing  Laboratory


Farmington CT – January 5, 2015 – CaroGen Corporation today announced that it has chosen UConn’s Technology Incubation Program (TIP) in Farmington to establish a laboratory footprint. This expansion will allow CaroGen to more aggressively pursue the advancement of its proprietary virus-like vesicle (VLV) vaccine technology, development of its HBV vaccine program and evaluation of other potential candidate infectious disease vaccines.


-Click to Read More-



CaroGen Receives $500,000 Investment from Connecticut Bioscience Innovation Fund (CBIF)


Hamden CT – December 10, 2014 – CaroGen has been awarded $500,000 from the CBIF to support the continued development of CaroGen's therapeutic Hepatitis B Virus (HBV) vaccine.


-Click to Read More-



CaroGen Wins Entrepreneur Innovation Award from CTNext


Hamden CT – April 3, 2014 – CaroGen was awarded a $10,000 grant by CTNext, a component of Connecticut’s innovation ecosystem to support the success of companies and entrepreneurs, to further support development of its therapeutic vaccine for chronic Hepatitis B (CHB) viral infection.


-Click to Read More-








CaroGen Corporation


Cell & Genome Sciences Building R2802


400 Farmington Ave


Farmington, CT 06032


Tel: 203-815-5782

Copyright 2013 CaroGen Corporation

About Us